145 related articles for article (PubMed ID: 16611343)
1. Sequential kidney/islet transplantation: efficacy and safety assessment of a steroid-free immunosuppression protocol.
Toso C; Baertschiger R; Morel P; Bosco D; Armanet M; Wojtusciszyn A; Badet L; Philippe J; Becker CD; Hadaya K; Majno P; Bühler L; Berney T;
Am J Transplant; 2006 May; 6(5 Pt 1):1049-58. PubMed ID: 16611343
[TBL] [Abstract][Full Text] [Related]
2. Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience.
Froud T; Ricordi C; Baidal DA; Hafiz MM; Ponte G; Cure P; Pileggi A; Poggioli R; Ichii H; Khan A; Ferreira JV; Pugliese A; Esquenazi VV; Kenyon NS; Alejandro R
Am J Transplant; 2005 Aug; 5(8):2037-46. PubMed ID: 15996257
[TBL] [Abstract][Full Text] [Related]
3. Islet of Langerhans allogeneic transplantation at the University of Geneva in the steroid free era in islet after kidney and simultaneous islet-kidney transplantations.
Berney T; Bucher P; Mathe Z; Andres A; Bosco D; Mage R; Toso C; Oberholzer J; Becker C; Philippe J; Bühler L; Morel P
Transplant Proc; 2004 May; 36(4):1121-2. PubMed ID: 15194390
[TBL] [Abstract][Full Text] [Related]
4. Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression: the National Institutes of Health experience.
Hirshberg B; Rother KI; Digon BJ; Lee J; Gaglia JL; Hines K; Read EJ; Chang R; Wood BJ; Harlan DM
Diabetes Care; 2003 Dec; 26(12):3288-95. PubMed ID: 14633816
[TBL] [Abstract][Full Text] [Related]
5. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen.
Shapiro AM; Lakey JR; Ryan EA; Korbutt GS; Toth E; Warnock GL; Kneteman NM; Rajotte RV
N Engl J Med; 2000 Jul; 343(4):230-8. PubMed ID: 10911004
[TBL] [Abstract][Full Text] [Related]
6. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
[TBL] [Abstract][Full Text] [Related]
7. Successful simultaneous islet-kidney transplantation using a steroid-free immunosuppression: two-year follow-up.
Lehmann R; Weber M; Berthold P; Züllig R; Pfammatter T; Moritz W; Mädler K; Donath M; Ambühl P; Demartines N; Clavien And PA; Andreia Spinas G
Am J Transplant; 2004 Jul; 4(7):1117-23. PubMed ID: 15196070
[TBL] [Abstract][Full Text] [Related]
8. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation.
Sarwal MM; Vidhun JR; Alexander SR; Satterwhite T; Millan M; Salvatierra O
Transplantation; 2003 Nov; 76(9):1331-9. PubMed ID: 14627912
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous islet and kidney transplantation in seven patients with type 1 diabetes and end-stage renal disease using a glucocorticoid-free immunosuppressive regimen with alemtuzumab induction.
Tan J; Yang S; Cai J; Guo J; Huang L; Wu Z; Chen J; Liao L
Diabetes; 2008 Oct; 57(10):2666-71. PubMed ID: 18633105
[TBL] [Abstract][Full Text] [Related]
10. Experience with a novel efalizumab-based immunosuppressive regimen to facilitate single donor islet cell transplantation.
Turgeon NA; Avila JG; Cano JA; Hutchinson JJ; Badell IR; Page AJ; Adams AB; Sears MH; Bowen PH; Kirk AD; Pearson TC; Larsen CP
Am J Transplant; 2010 Sep; 10(9):2082-91. PubMed ID: 20883542
[TBL] [Abstract][Full Text] [Related]
11. Clinical islet transplantation in type 1 diabetes mellitus: results of Australia's first trial.
O'Connell PJ; Hawthorne WJ; Holmes-Walker DJ; Nankivell BJ; Gunton JE; Patel AT; Walters SN; Pleass HC; Allen RD; Chapman JR
Med J Aust; 2006 Mar; 184(5):221-5. PubMed ID: 16515432
[TBL] [Abstract][Full Text] [Related]
12. Histopathological study of intrahepatic islets transplanted in the nonhuman primate model using edmonton protocol immunosuppression.
Hirshberg B; Mog S; Patterson N; Leconte J; Harlan DM
J Clin Endocrinol Metab; 2002 Dec; 87(12):5424-9. PubMed ID: 12466330
[TBL] [Abstract][Full Text] [Related]
13. Islet transplantation with alemtuzumab induction and calcineurin-free maintenance immunosuppression results in improved short- and long-term outcomes.
Froud T; Baidal DA; Faradji R; Cure P; Mineo D; Selvaggi G; Kenyon NS; Ricordi C; Alejandro R
Transplantation; 2008 Dec; 86(12):1695-701. PubMed ID: 19104407
[TBL] [Abstract][Full Text] [Related]
14. Comparison of sirolimus alone with sirolimus plus tacrolimus in type 1 diabetic recipients of cultured islet cell grafts.
Gillard P; Ling Z; Mathieu C; Crenier L; Lannoo M; Maes B; Roep B; Gorus F; Pipeleers D; Keymeulen B
Transplantation; 2008 Jan; 85(2):256-63. PubMed ID: 18212631
[TBL] [Abstract][Full Text] [Related]
15. Improving efficacy of clinical islet transplantation with iodixanol-based islet purification, thymoglobulin induction, and blockage of IL-1β and TNF-α.
Matsumoto S; Takita M; Chaussabel D; Noguchi H; Shimoda M; Sugimoto K; Itoh T; Chujo D; SoRelle J; Onaca N; Naziruddin B; Levy MF
Cell Transplant; 2011; 20(10):1641-7. PubMed ID: 21396171
[TBL] [Abstract][Full Text] [Related]
16. Elevated portal vein drug levels of sirolimus and tacrolimus in islet transplant recipients: local immunosuppression or islet toxicity?
Desai NM; Goss JA; Deng S; Wolf BA; Markmann E; Palanjian M; Shock AP; Feliciano S; Brunicardi FC; Barker CF; Naji A; Markmann JF
Transplantation; 2003 Dec; 76(11):1623-5. PubMed ID: 14702535
[TBL] [Abstract][Full Text] [Related]
17. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients.
Ciancio G; Burke GW; Suzart K; Roth D; Kupin W; Rosen A; Olson L; Esquenazi V; Miller J
Transplantation; 2002 Apr; 73(7):1100-6. PubMed ID: 11965039
[TBL] [Abstract][Full Text] [Related]
18. Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients.
Bruce DS; Sollinger HW; Humar A; Sutherland DE; Light JA; Kaufman DB; Alloway RR; Lo A; Stratta RJ
Transplantation; 2001 Nov; 72(10):1637-43. PubMed ID: 11726823
[TBL] [Abstract][Full Text] [Related]
19. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of daclizumab induction for primary kidney transplant recipients in combination with tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.
Ciancio G; Burke GW; Suzart K; Vaidya A; Roth D; Kupin W; Mattiazzi A; Rosen A; Esquenazi V; Miller J
Transplant Proc; 2003 Mar; 35(2):873-4. PubMed ID: 12644172
[No Abstract] [Full Text] [Related]
[Next] [New Search]
